These results may be in part due to one of the major targets of miR-222 identified in other malignancies, PTEN, not being as involved in AML development as it is in other malignancies, although further studies on larger cohorts are needed for a conclusive result [19,22,37]. The gene discussed is PTEN; the disease is acute myeloid leukemia.